Clinical trials: Cryopyrin-Associated Periodic Syndromes (CAPS)
Healthy Volunteers
A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study
The study design of this trial is a Dose-Block Randomized, Placebo controlled (Double-blind), Active Controlled(Open-label), Dose-escalation.
- Trial name
- NCT02175056
- Testing
- HL2351, Kineret(Anakinra)
- Where
- South Korea
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
Background: Anakinra is a drug used to treat people with certain diseases that affect their immune systems. Sometimes anakinra can cause proteins under the skin to clump together.
- Trial name
- NCT06974877
- Testing
- 124I AT-01
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cryopyrin-Associated Periodic Syndromes (CAPS)
HL2351 CAPS Phase II Study
This is an open label, single arm trial to evaluate the efficacy, safety, and pharmacokinetics of HL2351 in patients with cryopyrin associated periodic syndromes (CAPS).
- Trial name
- NCT02853084
- Testing
- HL2351
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Handok Inc.
Muckle-Wells Syndrome, Schnitzler Syndrome
Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
This is a single-center open label study of the IL-1 transfusion protein rilonacept in subjects with Muckle-Wells syndrome (MWS), or Schnitzler syndrome (SchS) in Germany.
- Trial name
- ACCILTRA1 (NCT01045772)
- Testing
- rilonacept
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Charite University, Berlin, Germany
Cryopyrin-associated Periodic Syndromes (CAPS)
Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)
- Trial name
- NCT07247266
- Testing
- JTE-162
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Akros Pharma Inc.
Cryopyrin-Associated Periodic Syndromes
A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)
This is a prospective cohort study to observe the efficacy and safety of tranilast in CAPS patients. The investigators would analyze the changes in Auto-Inflammatory Diseases Activity Index (AIDAI) before and after treatment as…
- Trial name
- NCT03923140
- Testing
- Tranilast
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Peking Union Medical College Hospital
Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS)
Ilaris NIS in Korea
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes…
- Conditions
- Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF), TNF Receptor Associated Periodic Syndrome (TRAPS)
- Trial name
- REASSURE (NCT06838143)
- Testing
- Ilaris
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Familial Cold Urticaria
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria.
- Trial name
- NCT00214851
- Testing
- Kineret (anakinra)
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Nova Scotia Health Authority
Colorectal Adenoma, Colorectal Neoplasms
Adenoma Detection Rate in Colonoscopy Performed With EndoRings
The study is designed to examine whether colonoscopy using an EndoRings cap has a higher adenoma detection rate than conventional colonoscopy.
- Trial name
- NCT03219918
- Testing
- EndoRings II Distal Attachment
- Where
- Denmark
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Zealand University Hospital
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Cryopyrin Associated Periodic Syndrome
Adult Outcomes of Children With CAPS
The patients included in this study were followed up in the Internal Medicine and Paediatrics Departments of the Lille CHU, the Paediatric Rheumatology and Immunology Department of the Necker Enfant Malade Hospital in Paris and…
- Trial name
- CAPS (NCT04856540)
- Where
- France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Lille
Cryopyrin-Associated Periodic Syndromes
Kineret CAPS Post Authorisation Study
A non-interventional, post authorization safety study to evaluate the safety of Kineret in the treatment of Cryopyrin Associated Periodic Syndromes (CAPS) in routine clinical care with regard to serious infections, malignancies…
- Trial name
- NCT02326376
- Testing
- anakinra (Kineret)
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Swedish Orphan Biovitrum
Autoinflammatory Disease, FMF
Are Mast Cells Involved in Autoinflammatory Diseases
Autoinflammatory diseases (AID) are caused by innate immunity dysregulation. AID pathophysiology is only partly understood, especially in the case of unclassified AID.
- Conditions
- Autoinflammatory Disease, FMF, TRAPS, MKD
- Trial name
- INFLAMAST (NCT05292768)
- Where
- France
- Volunteers
- 590 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy Volunteer, Rheumatoid Arthritis
Phenomics in Autoimmune and Inflammatory Diseases
The family of inflammatory/autoimmune systemic diseases (IAD) form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammatory diseases with some autoimmune components, and…
- Conditions
- Healthy Volunteer, Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome
- Trial name
- TRANSIMMUNOM (NCT02466217)
- Testing
- 1: AID groups, 2: Control groups
- Where
- 2 sites in France
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Muckle Wells Syndrome, Autoinflammatory
A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
Background: Autoinflammatory diseases are illnesses that produce episodes of inflammation such as fever, rash, or joint swelling.
- Conditions
- Muckle Wells Syndrome, Autoinflammatory, Behcet's Disease
- Trial name
- NCT01211977
- Testing
- XOMA 052
- Where
- United States
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This trial will assess the safety, efficacy and tolerability of ACZ885 in patients aged 4 years and younger with cryopyrin associated periodic syndromes (CAPS)
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT01302860
- Testing
- ACZ885
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Hypersensitivity, Immediate, Autoinflammatory Syndromes
Pathogenesis of Physical Induced Urticarial Syndromes
Background: Urticaria is a common itchy skin disorder that may occur spontaneously or on exposure to a physical trigger (called physical urticaria).
- Conditions
- Hypersensitivity, Immediate, Autoinflammatory Syndromes, Physical Urticaria, Familial Cold Autoinflammatory Syndrome
- Trial name
- NCT00887939
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
NOMID, CINCA Syndrome
Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
This study will examine whether a medicine called canakinumab is safe and effective for treating patients with neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurologic, cutaneous…
- Trial name
- NCT00770601
- Testing
- Canakinumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
To date there are no approved effective therapies for the treatment of cryopyrin-associated periodic syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), or Neonatal Onset…
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT00991146
- Testing
- canakinumab
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Cryopyrin-Associated Periodic Syndrome
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
This is a Phase 2 study to investigate the safety and efficacy of ATI-450 for the Maintenance of Remission in Patients with Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed with Anti-IL-1 Therapy.
- Trial name
- NCT04524858
- Testing
- ATI-450
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Aclaris Therapeutics, Inc.